Compounds > azintamid
Page last updated: 2024-11-06

azintamid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

azintamid: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71105
CHEMBL ID2104678
CHEBI ID135068
SCHEMBL ID1236142
MeSH IDM0058166

Synonyms (69)

Synonym
azintamid
(6-chlorpyridazin-3-ylthio)diethylacetamide
(3-chlor-pyridazinyl-(6)-thio)-essigsaeurediaethylamid [german]
brn 0885011
2-((6-chloro-3-pyridazinyl)thio)-n,n-diethylacetamide
einecs 217-384-2
azintamide [inn]
n,n-diethyl-2-(6-(3-chloropyridazinyl)mercapto)acetamide
(3-chloro-pyridazinyl-(6)-thio)-acetic acid diethylamide
ora-gallin
azintamida [inn-spanish]
nsc 291837
acetamide, 2-((6-chloro-3-pyridazinyl)thio)-n,n-diethyl-
x 23
n,n-diethyl-2-(6-(3-chloropyridazinyl)thio)acetamide
azintamidum [inn-latin]
acetamide, 2-(6-chloro-3-pyridazinylthio)-n,n-diethyl-
azintamide (inn)
ora-gallin purum
colerin (tn)
D07485
oragalin
1830-32-6
st 9067
(3-chloro-pyridazinyl-(6)-thio)acetic acid diethylamide
wln: t6nnj cg fs1vn2&2
(3-chlor-pyridazinyl-(6)-thio)-essigsaeurediaethylamid
oragallin purum
colerin
biloral
oragallin
azintamide
n,n-diethyl (6-chloropyridazin-3-ylthio)acetamide
nsc291837
azinthiamide
nsc-291837
oragal
bilipurum
CHEBI:135068
2-(6-chloropyridazin-3-yl)sulfanyl-n,n-diethylacetamide
acz6l64b41 ,
azintamidum
5-23-11-00092 (beilstein handbook reference)
unii-acz6l64b41
azintamida
CHEMBL2104678
st-9067 ,
azintamide [who-dd]
azintamide [mi]
azintamide [mart.]
SCHEMBL1236142
acetamide,2-[(6-chloro-3-pyridazinyl)thio]-n,n-diethyl-
smr004703523
MLS006011938
AC-24006
DTXSID50171370
AKOS025401654
Z221446992
SR-01000945218-1
SR-01000945218-2
sr-01000945218
FT-0733632
DB13992
bilipurum; colerin; oragalin
Q27273875
2-[(6-chloropyridazin-3-yl)sulfanyl]-n,n-diethylacetamide
EN300-1700027
CS-0066088
HY-117437

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The changes of symptoms score of upper abdominal distention, upper abdominal pain or discomfort anorexia and effective rate as well as adverse events were recorded."( [Efficacy and safety of compound azintamide on dyspepsia symptoms in a multicentre self-controlled trial].
Han, SM; Hao, JY; Liu, YL; Qian, JM; Xie, PY; Xu, L; Yang, YS; Zhang, M; Zhao, HC; Zhu, LM, 2008)		0.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aryl sulfideAny organic sulfide in which the sulfur is attached to at least one aromatic group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (50.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.92 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (28.57%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
domperidone
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.		8.4511benzimidazoles;
heteroarylpiperidine		antiemetic;
dopaminergic antagonist
cellulase
Cellulase: An endocellulase with specificity for the hydrolysis of 1,4-beta-glucosidic linkages in CELLULOSE, lichenin, and cereal beta-glucans.. beta-cellotriose : A cellotriose with a beta-configuration at the anomeric position.		2.1510cellotriose
ConditionIndicatedRelationship StrengthStudiesTrials
Indigestion
[description not available]		03.8421
Dyspepsia
Impaired digestion, especially after eating.		03.8421
Liver Dysfunction
[description not available]		01.9410
Gall Bladder Diseases
[description not available]		01.9410
Liver Diseases
Pathological processes of the LIVER.		01.9410
Palmoplantaris Pustulosis
[description not available]		01.9610
Psoriasis
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.		06.9610